World's Best Scientists 2026 revealed!
Michael A.S. Jewett

Michael A.S. Jewett

D-Index & Metrics

Medicine

D-Index
96
Citations
29740
World Ranking
9776
National Ranking
391

Michael A.S. Jewett publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael A.S. Jewett sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 656 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael A.S. Jewett D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael A.S. Jewett sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael A.S. Jewett is affiliated with the University of Toronto in Canada and has contributed extensively to the field of medicine, with a particular focus on surgery, pulmonary and respiratory medicine, molecular biology, oncology, and public health.

The primary areas of research for Jewett include renal cell carcinoma treatment, bladder and urothelial cancer treatments, testicular diseases and treatments, renal and related cancers, urinary and genital oncology studies, sarcoma diagnosis and treatment, and economic and financial impacts of cancer.

Jewett has published in various reputable journals, including:

  • British Journal of Urology (13 publications)
  • The Journal of Urology (12 publications)
  • Journal of Clinical Oncology (10 publications)
  • Canadian Urological Association Journal (8 publications)
  • European Urology (6 publications)

Frequent co-authors throughout Jewett's research career include:

  • Robert J. Hamilton (18 coauthored papers)
  • Antonio Finelli (15 coauthored papers)
  • Girish S. Kulkarni (14 coauthored papers)
  • Lynn Anson-Cartwright (14 coauthored papers)
  • Peter Chung (13 coauthored papers)

Highlights among recent papers include:

  • "Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis," published in 2023 in The Lancet Oncology
  • "Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort," published in 2020 in European Urology
  • "FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†," published in 2020 in European Urology
  • "Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer," published in 2020 in European Urology Oncology
  • "Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma," published in 2021 in European Urology

Jewett's work mainly explores surgical approaches and oncological treatments related to urinary tract cancers, particularly bladder and renal cancers, as well as testicular disease monitoring. The research spans clinical outcomes, biomarker utility, and disease surveillance strategies, indicating a comprehensive approach to oncological surgery and treatment modalities.

Best Publications

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer ☆

    Michael A.S. Jewett;Kamal Mattar;Joan Basiuk;Christopher G. Morash

  • Clinical practice. Small renal mass.

    Inderbir S. Gill;Monish Aron;Debra A. Gervais;Michael A.S. Jewett

  • Testicular germ cell tumours

    Ewa Rajpert-De Meyts;Katherine A McGlynn;Keisei Okamoto;Michael A S Jewett

  • Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The surtime randomized clinical trial

    Axel Bex;Peter Mulders;Michael A.S. Jewett;John Wagstaff

  • Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

    Marc C. Smaldone;Alexander Kutikov;Brian L. Egleston;Daniel J. Canter

  • Techniques, Safety and Accuracy of Sampling of Renal Tumors by Fine Needle Aspiration and Core Biopsy

    Alessandro Volpe;John R. Kachura;William R. Geddie;Andrew J. Evans

  • Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance

    Christian Kollmannsberger;Torgrim Tandstad;Philippe L. Bedard;Gabriella Cohn-Cedermark

  • VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail

    Andrew J. Evans;Ryan C. Russell;Olga Roche;T. Nadine Burry

  • Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline

    Antonio Finelli;Nofisat Ismaila;Bill Bro;Jeremy Durack

  • Treatment of Localised Renal Cell Carcinoma

    Hendrik Van Poppel;Frank Becker;Jeffrey A Cadeddu;Inderbir S Gill

  • ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

    F Honecker;J Aparicio;D Berney;Jörg Beyer

  • Contemporary Results of Percutaneous Biopsy of 100 Small Renal Masses: A Single Center Experience

    Alessandro Volpe;Kamal Mattar;Antonio Finelli;John R. Kachura

  • Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic

    Girish S Kulkarni;Thomas Hermanns;Yanliang Wei;Bimal Bhindi

  • The Uncertainty Of Radio Frequency Treatment Of Renal Cell Carcinoma: Findings At Immediate And Delayed Nephrectomy

    Ricardo A. Rendon;John R. Kachura;Joan M. Sweet;Mark R. Gertner

  • Rationale for percutaneous biopsy and histologic characterisation of renal tumours.

    Alessandro Volpe;Antonio Finelli;Inderbir S. Gill;Michael A.S. Jewett

  • Retroperitoneal Lymphadenectomy for Testis Tumor with Nerve Sparing for Ejaculation

    Michael A.S. Jewett;Young-Soo P. Kong;Susan D. Goldberg;Jeremy F.G. Sturgeon

  • Radical Radiotherapy for Muscle Invasive Transitional Cell Carcinoma of the Bladder: Failure Analysis

    Mary K. Gospodarowicz;N.V. Hawkins;G.A. Rawlings;J.G. Connolly

  • The Y deletion gr/gr and susceptibility to testicular germ cell tumor

    Katherine L. Nathanson;Peter A. Kanetsky;Rachel Hawes;David J. Vaughn

Frequent Co-Authors

Neil Fleshner
Neil Fleshner Princess Margaret Cancer Centre
Antonio Finelli
Antonio Finelli University Health Network
Alexandre R. Zlotta
Alexandre R. Zlotta University Health Network
Padraig Warde
Padraig Warde Princess Margaret Cancer Centre
John Trachtenberg
John Trachtenberg University of Toronto
George M. Yousef
George M. Yousef University of Toronto
Mary K. Gospodarowicz
Mary K. Gospodarowicz Princess Margaret Cancer Centre
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
Andrew Evans
Andrew Evans University of Dundee
Steven A. Narod
Steven A. Narod University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Medicine doesn’t always mean becoming a doctor. There are several rewarding roles in healthcare that can be accessed with flexible, online degrees. These programs make it easier for students to balance work, family, and education, while often saving on tuition costs.

If you’re interested in the business side of healthcare, healthcare administration degrees provide training in leadership, policy, and management. For those aiming higher, the cheapest online mha programs offer a graduate-level pathway to top administrative positions.

For nursing professionals, advancing your career is possible with the most affordable online dnp programs, designed for nurses aiming for leadership or advanced clinical practice. Pharmacists can also move forward with a 3-year online pharmd, ideal for those seeking a quicker, cost-effective route to a doctorate.

Online programs in healthcare are evolving, providing accessible, respected avenues for students to achieve their career goals within the healthcare sector.

Best Scientists Citing Michael A.S. Jewett

Trending Scientists

Recently Published Articles